Back | Next |
home / stock / lxrx / lxrx message board
Subject | By | Source | When |
---|---|---|---|
We expect that the new joint guidelines issued | BooDog | investorshub | 04/19/2022 10:24:27 AM |
whytestocks: $LXRX News Article - Lexicon Welcomes New Guidelines for the Management of Heart Failur | whytestocks | investorshangout | 04/04/2022 4:00:56 PM |
Very interesting intraday recovery. News after close? | BooDog | investorshub | 01/14/2022 9:01:40 PM |
What do I dislike more than bleeders? | BooDog | investorshub | 01/13/2022 5:52:12 PM |
BooDog: Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. | BooDog | investorshangout | 01/13/2022 2:07:15 PM |
Might be my last add here, $3.58. | BooDog | investorshub | 01/12/2022 3:28:16 PM |
If this works out my 3.48's may see | BooDog | investorshub | 01/06/2022 6:05:20 PM |
Gap from last August fills 3.48. I'll bite. | BooDog | investorshub | 01/05/2022 8:34:07 PM |
VP, HUMAN RESOURCES form 3 filed. Initial statement. | BooDog | investorshub | 01/05/2022 2:01:17 PM |
Don't let the price action fool you, play | BooDog | investorshub | 01/03/2022 5:45:04 PM |
$LXRX 4.99 Golden Cross in progress. | BooDog | investorshub | 11/17/2021 5:44:32 PM |
Should have remembered what earnings do in this | BooDog | investorshub | 11/04/2021 7:38:08 PM |
Picking up some momentum! Great!! | BooDog | investorshub | 11/03/2021 7:11:48 PM |
Thanks Chupacabra Gigante!!! Yes, looking very good | BooDog | investorshub | 11/01/2021 3:01:06 PM |
200 DMA 5.32, 50 DMA 4.94. With a | BooDog | investorshub | 10/29/2021 3:59:30 PM |
Boo Dog | Chupacabra Gigante | investorshub | 10/26/2021 8:11:57 PM |
This just may get interesting. Let's see | BooDog | investorshub | 10/21/2021 7:56:54 PM |
Small bite here at $5. Next buy around | BooDog | investorshub | 10/19/2021 4:17:57 PM |
Did take a few off 6.23. Looking | BooDog | investorshub | 10/14/2021 3:18:48 PM |
Form 3's building their positions. I'm thinking | BooDog | investorshub | 10/08/2021 6:11:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early 2025 THE WOODLANDS, Texas, June 21, 2024 (GLOBE NEWSWIR...
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that clinical outcomes of RELIEF-DPN 1 support commencement of Lexiconȁ...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pha...